Resimmune^®

Angimmune welcomes inquiries on the licensing of its technology. Our first candidate Resimmune, is entering a pivotal Phase II trial (two-arm with an active comparator) for the treatment of Cutaneous T-Cell Lymphoma (CTCL). This trial is designed to support Fast Track Designation as well as a Marketing Application. Protocols are being developed to test Resimmune in the treatment of Aplastic anemia and the treatment of Multiple sclerosis. Resimmune is also in a Phase I/II trial to test the hypothesis that Resimmune can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens.

Orphan Drug Designation

Resimmune^® or A-dmDT390-bisFv(UCHT1) has been granted Orphan Drug Designation for the treatment of Cutaneous T-Cell Lymphoma (CTCL).

Collaboration Opportunities

Because a wide variety of antibody sequences can be used in the DT390/Pichia Platform, collaborations with other companies having proprietary antibodies may be mutually beneficial. Angimmune holds exclusive licenses from NIH of all intellectual property developed by Neville, Woo, and Liu.

---

Licensing inquiries – US and worldwide

Email: Paul Neville
Director of Operations